Drugs / TAK-441
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01204073 | Oct 2010 → Dec 2012 | basal cell carcinoma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-441 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01204073 ↗ |
| Action | Inhibit | “TAK-441, an Oral Hedgehog Signaling Pathway Inhibitor” NCT01204073 ↗1“Smoothened homolog antagonist” CHEMBL2205230 ↗ |
| Modality | Small molecule | — CHEMBL2205230 ↗ |
| Route | Oral | “administered as an oral tablet” NCT01204073 ↗ |
| Target | SMO | “Smoothened homolog antagonist” CHEMBL2205230 ↗ |